![]() Back to Annual Meeting
|
|
![]() Back to Annual Meeting
|
APHA Scientific Session and Event Listing |
Seth Himelhoch, MD, MPH1, John F. McCarthy, PhD, MPH2, Dara Ganoczy, MPH2, Deborah Medoff, PhD1, Amy M. Kilbourne, PhD2, Richard Goldberg, PhD1, Lisa Dixon, MD, MPH1, and Frederic Blow, PhD2. (1) Department of Pyschiatry, University of Maryland, 737 W. Lombard Street, Baltimore, MD 21201, (410) 706-2490, shimelho@psych.umaryland.edu, (2) Department of Psychiatry, University of Michigan, Veterans Affairs, SMITREC (11H), P.O. Box 130170, Ann Arbor, MI 48113-0170
Background: Although individuals with serious mental illness (SMI) are reported to have a high prevalence of Hepatitis C Virus (HCV), the results of these studies may be limited by non-representative, convenience samples, and lack of a non-SMI control groups. Methods: A cross-sectional study of patients in the Veterans Affairs (VA) health system who received at least 3 health care encounters during fiscal year 2002, comparing those with a diagnosis of schizophrenia or bipolar disorder (N=155,172) to a random sample of patients without these diagnoses (N = 67,965). Crude and adjusted logistic regression analyses evaluated the prevalence and predictors of HCV. Results: HCV was diagnosed in 7.1% of patients with schizophrenia, 8.1% of those with bipolar disorder, and 2.5% among patients with neither condition. We found a significant interaction between substance use and SMI diagnosis. Compared to patients without SMI, individuals with schizophrenia and co-occurring substance abuse had 6 times the odds of having a diagnosis of HCV, and those with bipolar disorder and co-occurring substance abuse had 7 times the odds. Even in the absence of substance abuse, diagnosis of schizophrenia and of bipolar disorder were associated with 40% and 60% greater odds of HCV, respectively. Those with bipolar disorder and substance use were significantly more likely to have HCV than those with schizophrenia and substance use. Conclusions: Substance abuse is a significant moderator of risks of HCV among patients with schizophrenia and with bipolar disorder. Improving substance abuse treatment and primary and secondary HCV prevention remains a critical goal.
Learning Objectives:
Keywords: Mental Health, Hepatitis C
Presenting author's disclosure statement:
Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
The 135th APHA Annual Meeting & Exposition (November 3-7, 2007) of APHA